EXEL News and Press, Exelixis Inc. From 03/13/23

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. ...

2023-03-10 10:07:00 ET After the market's sharp downturn in 2022, many stocks fell to attractive levels. And while some have started to recover this year, major indexes have yet to wipe away the losses they accumulated last year. Plenty of exciting companies still seem pretty cheap. Let...

2023-03-09 09:05:52 ET Exelixis ( NASDAQ: EXEL ) shares ticked higher in the pre-market trading Thursday after Wells Fargo launched its coverage on the cancer drugmaker with an Overweight recommendation and a $23 per share target citing the sales potential of its lead rev...

A phase 3 trial evaluating a combination of Exelixis' ( NASDAQ: EXEL ) Cabometyx (cabozantinib) and Roche ( OTCQX:RHHBY ) Genentech unit's Tecentriq (atezolizumab) in locally advanced or metastatic renal cell carcinoma has failed. The CONTACT-03 study was evaluating the combi...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 evaluated cabozantinib (CABOMETYX ® ) in combination with atezolizumab versus cabozantinib alone in patients with locally adv...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March: Cowen 43 rd Annual Health...

Summary Exelixis has strong revenue growth and a positive outlook. Past success with a growing industry ensures demand for its products. Dependent on a single product. Thesis Over the past year, Exelixis stock (EXEL) has fallen 14.78% reflecting an increased cost of ex...

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to sunitinib, regardless of IMDC risk score These three-year data – with a media...

Exelixis ( NASDAQ: EXEL ) is set to pay $35M for its Dutch partner Sairopa B.V. after the FDA cleared an Investigational New Drug (IND) to evaluate the cancer drug ADU-1805 in adults with advanced solid tumors, the companies announced Monday. ADU-1805 is a monoclonal antibody designed...

The U.S. Food and Drug Administration (FDA) cleared Exelixis ( NASDAQ: EXEL ) and Sairopa (Sairopa) drug ADU-1805 to enter human trial to treat adults with advanced solid tumors. Sairopa had filed an investigational new drug (IND) application to evaluate the safety and pharm...